Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms ARB-085, HPB-001, PB-001 |
Target |
Action inhibitors |
Mechanism EGFR exon 20 inhibitors(EGFR exon 20 Mutation inhibitors), Proteolysis |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | China | 15 May 2021 | |
Non-Small Cell Lung Cancer | Preclinical | United States | 15 May 2021 | |
Non-Small Cell Lung Cancer | Preclinical | United States | 15 May 2021 |